Trogenix has dosed the first patient in its Phase I/II ADePT trial testing TGX-007, a dual-payload gene therapy for glioblastoma, at sites in the UK and US. TGX-007 uses a proprietary Synthetic Super-Enhancer platform to selectively kill tumor cells and activate immune response, aiming to provide a one-time treatment with lasting protection. The trial will assess safety, optimal dosing, and efficacy in newly diagnosed and recurrent glioblastoma patients, with potential to expand to other solid tumors. Early clinical data will guide further development of this innovative cancer therapy.
B2B ecommerce platform migrations typically succeed at launch but face revenue losses in the 30 to 90 days afterward due to failures in custom pricing rules, system integrations, and SEO ranking drops. These issues arise because post-launch monitorin...
Alamos Gold announced a quarterly dividend of $0.04 per share payable on June 25, 2026, to shareholders of record as of June 11, 2026. The company has repurchased 753,600 shares at a cost of $30 million in May 2026 under its Normal Course Issuer Bid....
Xunlei Limited announced a 54.1% year-over-year revenue increase to $98.6 million in Q1 2026, fueled by a 26.2% rise in subscription revenue and an 89.3% surge in overseas audio live-streaming revenue. Gross profit grew 45.8% to $57.7 million, though...
Electrolux Group announced a fully underwritten rights issue of approximately SEK 9 billion, approved by its Board and an Extraordinary General Meeting. The prospectus for this rights issue was approved by the Swedish Financial Supervisory Authority ...
US stock futures fell following US strikes on Iranian drone sites near the Strait of Hormuz, heightening Middle East tensions. Major indices showed slight declines, with the Russell 2000 small-cap index down. Earnings reports drew attention: Snowflak...
